Selective estrogen receptor modulator with estrogen does not affect the proliferation and apoptosis of uterine leiomyoma cells

The administration of menopausal hormone therapy (MHT) in women with uterine leiomyomas is still debated. The purpose of this article is to study the proliferation and apoptosis of uterine leiomyoma cells under the impact of selective estrogen receptor modulator (SERM) combined with estrogen. Primar...

Full description

Saved in:
Bibliographic Details
Published in:Translational cancer research 2020-09, Vol.9 (9), p.5390-5400
Main Authors: Lv, Shu-Lan, Wang, Rui, Xue, Xue, Zhao, Lan-Bo, Tuo, Xiao-Qian, Ma, Si-Jia, Liang, Dong-Xin, Wang, Yi-Ran, Feng, Xue, Li, Qing, Wang, Qi, Han, Lu, Li, Qi-Ling
Format: Article
Language:English
Subjects:
Original
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The administration of menopausal hormone therapy (MHT) in women with uterine leiomyomas is still debated. The purpose of this article is to study the proliferation and apoptosis of uterine leiomyoma cells under the impact of selective estrogen receptor modulator (SERM) combined with estrogen. Primary cultured uterine leiomyoma cells in the perimenopausal period were treated with estrogen (17-beta estradiol) + SERM (raloxifene) as the tissue selective estrogen complex (TSEC) group, while both estrogen + medroxyprogesterone acetate (E+P) and estrogen (E) alone as were used as control groups. The expression of proliferating cell nuclear antigen (PCNA) and B-cell lymphoma-2 (Bcl-2) proteins was assessed by methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay and western-blot analysis, respectively. The proliferation in the TSEC group was weaker than the control groups (P
ISSN:2218-676X
2219-6803
DOI:10.21037/tcr-19-3022a